BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...provide runway By Jeff Cranmer, Executive Editor After its $135 million series C raise Wednesday, Vividion...
...programs with preclinical proof of principle in hand. But Hatfield demurred when asked by BioCentury about Vividion’s...
...not-too-distant future.” Vividion is also developing an undisclosed transcription factor with Bristol Myers Squibb Co. (NYSE:BMY).Vividion’s...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...as CFO. He was previously CFO of Pharming Group N.V. (Euronext:PHARM).Patricia “Patty” Allen joined oncology and immunology company Vividion Therapeutics Inc....
...as chair of its Research Triangle Park, N.C., chapter. BC Staff Ionis Pharmaceuticals Pacific Biosciences Sana Biotechnology Purespring Therapeutics eFFECTOR Therapeutics Constellation Pharmaceuticals Vividion T2...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...compounds that recruit the ligases RNF114, RNF4 and KEAP1.Vividion Therapeutics Inc....
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...raised a crossover round in June, while Vividion Therapeutics Inc....
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...platform companies are enormously expensive to build,” he said, comparing HotSpot to Frontier Medicines Corp., Vividion Therapeutics Inc....
...raised $67 million in its series A round last year, according to BioCentury’s BCIQ database. Vividion...
BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

...With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective...
...which the pharma has expertise, and enable Vividion to explore hundreds of underexploited ubiquitin ligases. Vividion...
...the partnership following its Celgene acquisition (see “Nextech-Led Round to Help Vividion to POC” ). Vividion...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...as interim CEO while the organization searches for a permanent replacement. Cancer and immunology company Vividion Therapeutics Inc....
...CSO. He was SVP and group head, oncology research and development at Pfizer Inc. (NYSE:PFE). Vividion...
...screening platform to identify candidates against previously undruggable targets (see “How Nextech-led Round will Help Vividion...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...proteasome. Bertozzi’s Lycia is Versant’s third play in targeted degradation; the firm also invested in Vividion Therapeutics Inc....
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...shape. Other companies seeking to drug allosteric sites on proteins include Revolution Medicines Inc. and Vividion Therapeutics Inc....
BioCentury | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

...without restrictions. It attracted former Global Head of Innovation at Johnson & Johnson and current Vividion Therapeutics Inc....
...market and have all the scars to show for it,” he said. The board includes Vividion Therapeutics Inc....
Items per page:
1 - 10 of 26
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...provide runway By Jeff Cranmer, Executive Editor After its $135 million series C raise Wednesday, Vividion...
...programs with preclinical proof of principle in hand. But Hatfield demurred when asked by BioCentury about Vividion’s...
...not-too-distant future.” Vividion is also developing an undisclosed transcription factor with Bristol Myers Squibb Co. (NYSE:BMY).Vividion’s...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...as CFO. He was previously CFO of Pharming Group N.V. (Euronext:PHARM).Patricia “Patty” Allen joined oncology and immunology company Vividion Therapeutics Inc....
...as chair of its Research Triangle Park, N.C., chapter. BC Staff Ionis Pharmaceuticals Pacific Biosciences Sana Biotechnology Purespring Therapeutics eFFECTOR Therapeutics Constellation Pharmaceuticals Vividion T2...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...compounds that recruit the ligases RNF114, RNF4 and KEAP1.Vividion Therapeutics Inc....
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...raised a crossover round in June, while Vividion Therapeutics Inc....
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...platform companies are enormously expensive to build,” he said, comparing HotSpot to Frontier Medicines Corp., Vividion Therapeutics Inc....
...raised $67 million in its series A round last year, according to BioCentury’s BCIQ database. Vividion...
BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

...With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective...
...which the pharma has expertise, and enable Vividion to explore hundreds of underexploited ubiquitin ligases. Vividion...
...the partnership following its Celgene acquisition (see “Nextech-Led Round to Help Vividion to POC” ). Vividion...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...as interim CEO while the organization searches for a permanent replacement. Cancer and immunology company Vividion Therapeutics Inc....
...CSO. He was SVP and group head, oncology research and development at Pfizer Inc. (NYSE:PFE). Vividion...
...screening platform to identify candidates against previously undruggable targets (see “How Nextech-led Round will Help Vividion...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...proteasome. Bertozzi’s Lycia is Versant’s third play in targeted degradation; the firm also invested in Vividion Therapeutics Inc....
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...shape. Other companies seeking to drug allosteric sites on proteins include Revolution Medicines Inc. and Vividion Therapeutics Inc....
BioCentury | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

...without restrictions. It attracted former Global Head of Innovation at Johnson & Johnson and current Vividion Therapeutics Inc....
...market and have all the scars to show for it,” he said. The board includes Vividion Therapeutics Inc....
Items per page:
1 - 10 of 26